Status:
UNKNOWN
Performance and Patient Acceptance of a Commercially Available Beverage as Compared to an Oral Glucose Solution for Oral Glucose Tolerance Tests in Cystic Fibrosis (CF) Patients Who Are Screened for CF-related Diabetes.
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
Cystic Fibrosis
Cystic Fibrosis-related Diabetes
Eligibility:
All Genders
18+ years
Brief Summary
Rationale: Cystic fibrosis (CF) is an incurable genetic disease that affects the pulmonary system, digestive system, reproductive system and the sweat glands. 85 percent of patients with cystic fibros...
Detailed Description
Cystic fibrosis (CF) is an incurable, genetic disorder that is caused by a defect in the cystic fibrosis transmembrane conductance regulator gene (CFTR-gene). The CFTR-gene synthesises the CFTR-protei...
Eligibility Criteria
Inclusion
- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Age ≥ 18
- Diagnosed with CF
- One of the following:
- Diagnosed with CFRD or IGT based on a raise fasting glucose level or OGTT.
- Pancreatic insufficiency, without CFRD
Exclusion
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Age \< 18
- Active infection or inflammation
- Use of glucose-lowering drugs and/or medication known to affect insulin secretion or insulin resistance, other than short-acting insulin.
- No informed consent
Key Trial Info
Start Date :
December 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05377502
Start Date
December 15 2021
End Date
December 31 2022
Last Update
May 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam UMC
Amsterdam, Woubruggestraat 28-huis, Netherlands, 1007